Main Management ETF Advisors LLC Trims Stake in Ascendis Pharma A/S (NASDAQ:ASND)

Main Management ETF Advisors LLC cut its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 8.2% in the fourth quarter, HoldingsChannel reports. The fund owned 5,696 shares of the biotechnology company’s stock after selling 512 shares during the period. Main Management ETF Advisors LLC’s holdings in Ascendis Pharma A/S were worth $784,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Rice Hall James & Associates LLC increased its holdings in shares of Ascendis Pharma A/S by 2.0% during the 4th quarter. Rice Hall James & Associates LLC now owns 163,888 shares of the biotechnology company’s stock valued at $22,562,000 after purchasing an additional 3,274 shares in the last quarter. abrdn plc increased its holdings in Ascendis Pharma A/S by 18.3% in the fourth quarter. abrdn plc now owns 187,180 shares of the biotechnology company’s stock valued at $25,769,000 after buying an additional 28,967 shares in the last quarter. Blue Trust Inc. increased its holdings in Ascendis Pharma A/S by 540.5% in the fourth quarter. Blue Trust Inc. now owns 506 shares of the biotechnology company’s stock valued at $76,000 after buying an additional 427 shares in the last quarter. New York State Common Retirement Fund raised its position in shares of Ascendis Pharma A/S by 14.0% in the fourth quarter. New York State Common Retirement Fund now owns 204,482 shares of the biotechnology company’s stock worth $28,151,000 after acquiring an additional 25,164 shares during the period. Finally, Proficio Capital Partners LLC acquired a new position in shares of Ascendis Pharma A/S in the fourth quarter worth about $1,725,000.

Ascendis Pharma A/S Stock Up 4.6%

Ascendis Pharma A/S stock opened at $161.52 on Wednesday. The company has a fifty day simple moving average of $156.29 and a 200-day simple moving average of $141.85. The firm has a market capitalization of $9.85 billion, a price-to-earnings ratio of -22.75 and a beta of 0.41. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The company had revenue of $123.97 million for the quarter, compared to the consensus estimate of $98.56 million. On average, research analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ASND. Evercore ISI lifted their price target on Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an “outperform” rating in a research note on Friday, May 2nd. Wedbush raised their price objective on Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an “outperform” rating in a report on Friday, May 2nd. Royal Bank of Canada upped their target price on Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an “outperform” rating in a research note on Friday, May 2nd. The Goldman Sachs Group increased their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $200.00 price target on shares of Ascendis Pharma A/S in a report on Monday. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $216.07.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.